Wipfli Financial Advisors’s Arcturus Therapeutics ARCT Stock Holding History

Wipfli Financial Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1K	Buy	+46	New	+$772	﹤0.01%	2365

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wipfli Financial Advisors's ARCT Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Arcturus Therapeutics (ARCT) in Q3 2022: 46 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #2365 among its holdings.

116 funds tracked by Wall St. Rank hold ARCT as of Q3 2022.

Wipfli Financial Advisors held 46 shares of Arcturus Therapeutics worth $1K as of Q3 2022.
Arcturus Therapeutics was a new Wipfli Financial Advisors position in Q3 2022.
Arcturus Therapeutics made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2365 holding.
116 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.